Thermo Fisher Scientific launches Detachable Dynabeads to enhance cell therapy development and production

Thermo Fisher Scientific has unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads)*. These latest products expand on Thermo Fisher’s CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control.

Studies have shown that a balance of CD4+ and CD8+ Chimeric Antigen Receptor (CARs) seem most effective for CAR-T cell therapy. The specific binding properties of the new CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 products enable efficient isolation of CD4+ and CD8+ T cells, minimize cell stress and ensure high purity and yield of the desired cell populations.

When used together with the CTS Detachable Dynabeads Release Buffer, these products empower users with a first-of-its-kind cGMP cell selection technology that has an active release mechanism for process development, clinical trial and commercial manufacturing uses.

As a result, users can achieve more process flexibility and gain greater control over cell purity, yield and phenotype, which can help cell therapy developers bring life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancers.

The CTS Detachable Dynabeads platform works within Thermo Fisher Scientific’s modular, closed and automated cell therapy manufacturing workflow. In combination with Thermo Fisher Scientific’s Gibco Cell Therapy Systems (CTS) portfolio of products, including the Gibco CTS DynaCellect™ Magnetic Separation System, CTS Detachable Dynabeads allow users to shorten their manufacturing workflow by decreasing the time for steps downstream of cell isolation.

Thermo Fisher’s CTS portfolio of products are manufactured according to cGMP, designed to meet applicable cell therapy standards, and include traceability and regulatory documentation to help customers transition from research to clinical trials and commercial production.

“As the number of CAR-T cell clinical trials grew by 125% from 2016 to 2022, biotech and biopharma companies are facing ongoing challenges across process development, clinical trials and commercial manufacturing,” said Sara Henneman, general manager of Thermo Fisher Scientific’s cell culture and cell therapy business.

“The Dynabeads magnetic core is currently used in over 200 active clinical trials as well as several cell therapy drugs already approved for use. Our CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 represent the latest products from our platform that is accelerating innovation and increasing productivity for cell therapy manufacturers.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>